Zaburzenia mowy we wczesnej fazie choroby Alzheimera. Studium przypadków

Potocka-Pirosz, Kamila

doi:10.31338/uw.9788323540694

Cited by 1 publication

(1 citation statement)

References 71 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…At this stage, the role of the caregiver should be limited primarily to discreetly supporting the ward in everyday life and to encouraging him to be active and train his memory regularly. [3] In the second, medium-advanced stage of the disease, difficulties in communicating with the environment are very clear. Gradually increasing behavioral disorders dominate, such as aimless walking, making the same movements, restlessness, wandering, sudden outbursts of anger, verbal, but often also physical aggression.…”

Section: Disease Stages and Changes In Communicationsmentioning

confidence: 99%

Combination of psycho- and pharmacotherapy as a modern method of treatment of Alzheimer's disease.

PRÓCHNICKA

NOWAK

SIWEK

et al. 2023

J Educ Health Sport

View full text Add to dashboard Cite

Introduction: Alzheimer's disease is a degenerative disease of the brain, caused by the deposition of beta-amyloid and tau protein. It is characterized by progressive memory and behavior disorders which, over time, completely prevent the patient from functioning properly in everyday life, performing work and disrupting social contacts. Communication problems arise and patients forget more and more words. Unfortunately, we are not able to completely stop the progression of this disease, but we can only delay its development. To delay the progression of the disease, pharmacotherapy includes acetylcholinesterase inhibitors and NMDA receptor antagonists. Matherials and methods: This article, based on a PubMed review of available research, examines the impact of rivastigmine, donepezil, memantine and psychotherapy on delaying disease progression. Results: A number of studies have investigated the effect of 6-12 milligrams of rivastigmine, 10 milligrams of donepezil and 20 milligrams of memantine on patients' ability to communicate. The results were checked using the MMSE, ADAS or SIB scales and interviews conducted regularly by clinicians. In addition, patients were subjected to various forms of psychotherapy, including reminiscence therapy and cognitive therapy. All groups experienced significantly less deterioration in their functional stage of disease compared to the placebo groups. Conclusions: The best results in the treatment of Alzheimer's disease can be obtained by combining pharmacological therapy with non-pharmacological effects. Thanks to this form of treatment, the progression of the disease is delayed, and patients retain their communication abilities for longer.

show abstract

Section: Disease Stages and Changes In Communicationsmentioning

confidence: 99%